Skip to main content

Table 2 Usage of drugs in those with and without resistant hypertension

From: Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country

Name of drug Number of patients (%) p value*
  All Resistant Non resistant  
  (n = 277) (n = 53) (n = 224)  
Anti-hypertensives     
  ACEI 151 (54.5%) 37 (69.8%) 114 (50.9%) <0.05
  α-blockers 21 (7.6%) 14 (26.4%) 7 (3.1%) <0.001
  ARB 94 (33.9%) 22 (41.5%) 72 (32.1%) NS
  β-blockers 143 (51.6%) 38 (71.7%) 105 (46.9%) <0.01
  CCBs 131 (47.3%) 29 (54.7%) 102 (45.5%) NS
  Furosemide 59 (21.3%) 26 (49.1%) 33 (14.7%) <0.001
  Spiranolactone 8 (2.9%) 6 (11.3%) 2 (0.9%) <0.01
  Thiazide 34 (12.3%) 16 (30.2%) 18 (8.0%) <0.001
Other drugs     
  Anti platelets 201 (72.6%) 37 (69.8%) 174 (77.7%) NS
  Lipid lowering drugs 152 (54.9%) 25 (47.1%) 127 (56.7%) NS
  Nitrates 139 (50.2%) 26 (49.1%) 113 (50.4%) NS
  1. ACEI Antgiotensin Converting Enzyme Inhibitors, ARB Angiotensin-II Receptor Blockers, CCB Calcium Channel Blockers, NS Not Significant; *, p values for ‘Resistant’ Vs. ‘Non-resistant’ groups.